160 related articles for article (PubMed ID: 15485325)
1. Serum tumor markers in patients with breast cancer.
Lumachi F; Basso SM
Expert Rev Anticancer Ther; 2004 Oct; 4(5):921-31. PubMed ID: 15485325
[TBL] [Abstract][Full Text] [Related]
2. Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer.
Molina R; Filella X; Zanon G; Pahisa J; Alicarte J; Munoz M; Farrus B; Ballesta AM
Anticancer Res; 2003; 23(2A):1043-50. PubMed ID: 12820345
[TBL] [Abstract][Full Text] [Related]
3. [Biomarkers in breast cancer].
Kurebayashi J
Gan To Kagaku Ryoho; 2004 Jul; 31(7):1021-6. PubMed ID: 15272579
[TBL] [Abstract][Full Text] [Related]
4. [Clinical usefulness of tumor markers in breast cancer].
Konishi K; Karaki K; Watanabe K; Tsuda H; Konishi F
Rinsho Byori; 1993 Oct; 41(10):1108-15. PubMed ID: 8254956
[TBL] [Abstract][Full Text] [Related]
5. A decision support system for predicting a recurrence of breast cancer; a prospective study of serum tumour markers TAG 12, CA 15-3 and MCA.
Eskelinen M; Hippeläinen M; Carlsson L; Jonsson P; Alhava E
Anticancer Res; 1992; 12(5):1439-42. PubMed ID: 1444204
[TBL] [Abstract][Full Text] [Related]
6. [Tumor markers in breast cancer].
Kurebayashi J
Gan To Kagaku Ryoho; 2004 Nov; 31(12):2077-81. PubMed ID: 15570944
[TBL] [Abstract][Full Text] [Related]
7. [Tumor markers in breast cancer].
Inaji H; Komoike Y; Motomura K; Koyama H
Nihon Rinsho; 2000 Apr; 58 Suppl():140-5. PubMed ID: 11025987
[No Abstract] [Full Text] [Related]
8. [Considerations in rational use of tumor markers in breast carcinoma].
Crombach G
Praxis (Bern 1994); 1998 Apr; 87(17):589-94. PubMed ID: 9623326
[TBL] [Abstract][Full Text] [Related]
9. [The expression of NCC-ST-439, a tumor marker, in human breast cancer patients].
Miyahara E; Toi M; Wada T; Yamada H; Osaki A; Yanagawa E; Toge T
Gan No Rinsho; 1990 Sep; 36(11):2023-6. PubMed ID: 2232168
[TBL] [Abstract][Full Text] [Related]
10. [Tumor markers in breast cancer].
Harada Y; Ohuchi N; Ishida T; Ohnuki K
Gan To Kagaku Ryoho; 2001 Jul; 28(7):1035-40. PubMed ID: 11478135
[TBL] [Abstract][Full Text] [Related]
11. [An investigation of extracellular HER-2/NEU domain level in blood serum from breast cancer patients].
Korytova LI; Masliukova EA; Ovchinnikov IV; Filipenko MO; Korytov OV; Kudaĭbergenova AG
Vopr Onkol; 2010; 56(1):62-5. PubMed ID: 20361618
[TBL] [Abstract][Full Text] [Related]
12. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy.
Sandri MT; Johansson HA; Zorzino L; Salvatici M; Passerini R; Maisonneuve P; Rocca A; Peruzzotti G; Colleoni M
Cancer; 2007 Aug; 110(3):509-17. PubMed ID: 17559147
[TBL] [Abstract][Full Text] [Related]
13. Circulating hormone levels in breast cancer patients. correlation with serum tumor markers and the clinical and biological features of the tumors.
Hernández L; Nuñez-Villarl MJ; Martínez-Arribas F; Pollán M; Schneider J
Anticancer Res; 2005; 25(1B):451-4. PubMed ID: 15816610
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
[TBL] [Abstract][Full Text] [Related]
15. A comparative study of four serological tumor markers for the detection of breast cancer.
Clinton SR; Beason KL; Bryant S; Johnson JT; Jackson M; Wilson C; Holifield K; Vincent C; Hall M
Biomed Sci Instrum; 2003; 39():408-14. PubMed ID: 12724928
[TBL] [Abstract][Full Text] [Related]
16. Serological tumor markers for monitoring breast cancer.
Sölétormos G
Dan Med Bull; 2001 Nov; 48(4):229-55. PubMed ID: 11767127
[No Abstract] [Full Text] [Related]
17. Serum tumor markers.
Perkins GL; Slater ED; Sanders GK; Prichard JG
Am Fam Physician; 2003 Sep; 68(6):1075-82. PubMed ID: 14524394
[TBL] [Abstract][Full Text] [Related]
18. The prognostic and predictive values of circulating HER-2/neu extracellular domain in patients with metastatic breast cancer.
Abu-Khalaf MM; Harris L
Breast Cancer Res Treat; 2009 Apr; 114(3):513-5. PubMed ID: 18677560
[No Abstract] [Full Text] [Related]
19. Prognostic significance of changes in CA 15-3 serum levels during chemotherapy in metastatic breast cancer patients.
Tampellini M; Berruti A; Bitossi R; Gorzegno G; Alabiso I; Bottini A; Farris A; Donadio M; Sarobba MG; Manzin E; Durando A; Defabiani E; De Matteis A; Ardine M; Castiglione F; Danese S; Bertone E; Alabiso O; Massobrio M; Dogliotti L
Breast Cancer Res Treat; 2006 Aug; 98(3):241-8. PubMed ID: 16670941
[TBL] [Abstract][Full Text] [Related]
20. Tumor associated glycoprotein (TAG) 12: a new tumor marker in breast cancer.
Heinze T; Lichtenegger W
Anticancer Res; 2000; 20(6D):5049-52. PubMed ID: 11326666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
